Abstract
-
▴ Fomivirsen (ISIS 2922) is an antisense oligonucleotide which specifically inhibits replication of human cytomegalovirus. It achieves this by binding to complementary sequences on messenger RNA transcribed from the major immediate-early transcriptional unit of the virus. It is being developed for the treatment of cytomegalovirus retinitis.
-
▴ Mean maximum retinal concentrations of fomivirsen occurred ∼2 days after a single intravitreal injection in monkeys. The elimination half-life of fomivirsen (after a single 115μg dose) in monkey retina was 78 hours.
-
▴ Fomivirsen, administered as an intravitreal injection, significantly delayed progression of cytomegalovirus retinitis in patients with AIDS in preliminary clinical trials. In 18 patients with newly diagnosed, unilateral, peripheral cytomegalovirus retinitis treated with fomivirsen 165μg once weekly for 3 weeks, then 165μg every second week, the median time to disease progression was significantly longer than in 10 patients in whom fomivirsen treatment was deferred until early disease progression (71 vs 14 days).
-
▴ In patients with advanced, refractory, sight-threatening disease, treatment with fomivirsen 330μg once weekly for 3 weeks and then 330μg every 2 weeks (n = 34) or 330μg on days 1 and 15 and then monthly (n = 20) significantly delayed disease progression. The interpolated median time to disease progression was 90 days in both treatment groups.
-
▴ The most common adverse events reported in clinical trials of fomivirsen were increased intraocular pressure and mild to moderate intraocular inflammation. These events were generally transient or reversible with topical steroid treatment.
Similar content being viewed by others
References
Nokta MA, Hausrath SG, Pollard RB. Emerging treatments for viral retinitis. Biodrugs 1997 Jun; 7: 423–32
Temsamani J, Pari GS, Guinot P. Antisense approach for the treatment of cytomegalovirus infection. Expert Opin Invest Drug 1997 Sep; 6: 1157–67
Bonn D. Prospects for antisense therapy are looking brighter [news]. Lancet 1996 Mar 23; 347: 820
Fraser GL, Wahlestedt C. Applications of antisense technology to both basic and clinical research. Expert Opin Invest Drug 1995; 4(7): 637–46
Azad RF, Driver VB, Tanaka K. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob Agents Chemother 1993 Sep; 37: 1945–54
Anderson KP, Fox MC, Brown-Driver V, et al. Inhibition of human cytomegalovirus immediate-early gene expression by an anti-sense oligonucleotide complementary to immediate-early RNA. Antimicrob Agents Chemother 1996 Sep; 40: 2004–11
Henahan S. Fomivirsen focuses on the future in CMV retinitis. Inpharma 1998 May 23; 1138: 11
Azad RF, Brown-Driver V, Buckheit JRW, et al. Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs. Antiviral Res 1995 Oct; 28: 101–11
Mulamba GB, Hu A, Azad RF, et al. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922). Antimicrob Agents Chemother 1998 Apr; 42: 971–3
Leeds JM, Henry SP, Truong L, et al. Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit. Drug Metab Dispos 1997 Aug; 25: 921–6
Leeds JM, Henry SP, Bistner S, et al. Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys. Drug Metab Dispos 1998 Jul; 26: 670–5
Johnson DW, Muccioli C, Goldstein DA, et al. Safety and efficacy of fomivirsen in the treatment of CMV retinitis: a phase 3, controlled, multicenter study comparing immediate versus delayed treatment [abstract]. 8th International Congress on Infectious Diseases; 1998May 15–18; Boston, 135
Muccioli C, Goldstein DA, Johnson DW, et al. Fomivirsen safety and efficacy in the treatment of CMV retinitis: a phase 3, controlled, multicenter study comparing immediate versus delayed treatment [abstract]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb; Chicago, 224
Isis Pharmaceuticals, Carlsbad, California. 1998 (Data on file)
Hutcherson SL, Palestine AG, Cantrill HL, et al. Antisense oligonucleotide safety and efficacy for CMV retinitis in AIDS patients [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17; San Francisco, 204
Isis Vitravene may be considered for first-line use in CMV retinitis. The Pink Sheet 1998 Jul 27: 5
ISIS and CIBA vision present positive phase III results for anti-sense CMV retinitis drug advanced disease trial results support earlier findings; NDA submission imminent. Newswire; http://www.newspagecom 1998
FDA panel supports Isis’s antisense drug. Scrip Mag 1998 Jul 29 (2356): 22
Hudson HL, Boyer DS, Kupperman BD. Future trends and experimental modalities in the therapeutics of cytomegalovirus retinitis. Ophthal Clin North Am 1997; 10(1): 61–71
Isis/Ciba Antisense Compound Vitravene approved for CMV retinitis. The Pink Sheet 1998 Aug 31: 27
Isis Pharmaceuticals USA. Fomivirsen sodium prescribing information. 1998
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Perry, C.M., Balfour, J.A.B. Fomivirsen. Drugs 57, 375–380 (1999). https://doi.org/10.2165/00003495-199957030-00010
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199957030-00010